PL376363A1 - Chiralne pochodne kwasu oksazoloarylopropionowegoi ich zastosowanie jako agonistów PPAR - Google Patents

Chiralne pochodne kwasu oksazoloarylopropionowegoi ich zastosowanie jako agonistów PPAR

Info

Publication number
PL376363A1
PL376363A1 PL03376363A PL37636303A PL376363A1 PL 376363 A1 PL376363 A1 PL 376363A1 PL 03376363 A PL03376363 A PL 03376363A PL 37636303 A PL37636303 A PL 37636303A PL 376363 A1 PL376363 A1 PL 376363A1
Authority
PL
Poland
Prior art keywords
chirale
oxazole
acid derivatives
ppar agonists
arylpropionic acid
Prior art date
Application number
PL03376363A
Other languages
English (en)
Other versions
PL208743B1 (pl
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Georges Hirth
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL376363A1 publication Critical patent/PL376363A1/pl
Publication of PL208743B1 publication Critical patent/PL208743B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL376363A 2002-10-07 2003-10-06 Pochodne oksazolu, sposób ich wytwarzania, środki farmaceutyczne i zastosowanie tych pochodnych PL208743B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022286 2002-10-07

Publications (2)

Publication Number Publication Date
PL376363A1 true PL376363A1 (pl) 2005-12-27
PL208743B1 PL208743B1 (pl) 2011-06-30

Family

ID=32049977

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376363A PL208743B1 (pl) 2002-10-07 2003-10-06 Pochodne oksazolu, sposób ich wytwarzania, środki farmaceutyczne i zastosowanie tych pochodnych

Country Status (31)

Country Link
US (2) US6969725B2 (pl)
EP (1) EP1551814B1 (pl)
JP (1) JP4414886B2 (pl)
KR (1) KR100623819B1 (pl)
CN (1) CN100415727C (pl)
AR (1) AR041481A1 (pl)
AT (1) ATE402153T1 (pl)
AU (1) AU2003273949B2 (pl)
BR (1) BR0315114A (pl)
CA (1) CA2499721C (pl)
CO (1) CO5540385A2 (pl)
DE (1) DE60322408D1 (pl)
DK (1) DK1551814T3 (pl)
ES (1) ES2311110T3 (pl)
GT (1) GT200300218A (pl)
HR (1) HRP20050308A2 (pl)
IL (1) IL167250A (pl)
MX (1) MXPA05003392A (pl)
MY (1) MY143576A (pl)
NO (1) NO330171B1 (pl)
NZ (1) NZ538465A (pl)
PA (1) PA8584501A1 (pl)
PE (1) PE20040591A1 (pl)
PL (1) PL208743B1 (pl)
PT (1) PT1551814E (pl)
RU (1) RU2303593C2 (pl)
SI (1) SI1551814T1 (pl)
TW (1) TWI343915B (pl)
UY (1) UY28006A1 (pl)
WO (1) WO2004031162A1 (pl)
ZA (1) ZA200502664B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
KR20050075417A (ko) * 2002-11-15 2005-07-20 카딜라 헬스케어 리미티드 치환된 아랄킬 유도체
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
KR20080082541A (ko) * 2007-03-07 2008-09-11 동아제약주식회사 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN101805336B (zh) * 2009-02-13 2012-05-30 天津药物研究院 一类含色氨酸和异恶唑骨架的化合物、其制备方法和用途
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8637096B2 (en) 2009-12-04 2014-01-28 Curtis C. Stojan Compositions and method for enhancing insulin activity
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN102285933B (zh) 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
EP2758041B1 (de) 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
EE03765B1 (et) * 1996-08-19 2002-06-17 Japan Tobacco Inc. Propioonhappe derivaadid ja nende kasutamine
CN1130361C (zh) 1998-03-30 2003-12-10 日本烟草产业株式会社 异噁唑烷二酮化合物的制备方法
EP1077957B1 (en) * 1998-05-11 2004-08-04 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
KR20020060067A (ko) * 1999-04-06 2002-07-16 가와무라 요시부미 α-치환 카르복실산 유도체
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
DE10031657A1 (de) 2000-06-29 2002-01-24 Siemens Ag Hochfrequenz-Bauelement
US6930120B2 (en) * 2000-08-23 2005-08-16 Eli Lilly And Company Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
DE60211891T2 (de) * 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar

Also Published As

Publication number Publication date
GT200300218A (es) 2004-05-24
DK1551814T3 (da) 2008-10-27
IL167250A (en) 2010-12-30
UY28006A1 (es) 2004-04-30
EP1551814A1 (en) 2005-07-13
ATE402153T1 (de) 2008-08-15
RU2005114373A (ru) 2006-05-10
RU2303593C2 (ru) 2007-07-27
PE20040591A1 (es) 2004-08-30
TWI343915B (en) 2011-06-21
US6969725B2 (en) 2005-11-29
EP1551814B1 (en) 2008-07-23
DE60322408D1 (de) 2008-09-04
CA2499721C (en) 2011-03-15
MXPA05003392A (es) 2005-06-22
HK1083339A1 (en) 2006-06-30
CA2499721A1 (en) 2004-04-15
US20040116487A1 (en) 2004-06-17
ZA200502664B (en) 2006-02-22
KR100623819B1 (ko) 2006-09-13
NO330171B1 (no) 2011-02-28
HRP20050308A2 (en) 2006-07-31
CN1703406A (zh) 2005-11-30
ES2311110T3 (es) 2009-02-01
KR20050055750A (ko) 2005-06-13
TW200409761A (en) 2004-06-16
CO5540385A2 (es) 2005-07-29
US20050267180A1 (en) 2005-12-01
WO2004031162A1 (en) 2004-04-15
NO20051011L (no) 2005-05-02
PA8584501A1 (es) 2004-05-21
MY143576A (en) 2011-05-31
AU2003273949A1 (en) 2004-04-23
CN100415727C (zh) 2008-09-03
JP4414886B2 (ja) 2010-02-10
JP2006504709A (ja) 2006-02-09
SI1551814T1 (sl) 2008-10-31
BR0315114A (pt) 2005-08-16
NZ538465A (en) 2007-08-31
PT1551814E (pt) 2008-09-22
AR041481A1 (es) 2005-05-18
US7348349B2 (en) 2008-03-25
PL208743B1 (pl) 2011-06-30
AU2003273949B2 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
AP2004003110A0 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
PL376920A1 (pl) Podstawione pochodne 4-alkoksyoksazolu jako agoniści PPAR
AP2421A (en) Quinoline derivatives and their use as mycobacterial inhibitors.
TWI349671B (en) Novel adenine derivative and its use
ZA200410054B (en) Propionic acid derivatives and their use as hPPARsactivators.
IL163928A0 (en) Pyridinoylpiperidines as 5-htf agonists
AU2003206787A8 (en) Sulfonate derivatives and the use therof as latent acids
IL147821A0 (en) Benzoic acid derivatives and their use as ppar receptor agonists
IL181560A0 (en) 7-azaindoles and their use as ppar agonists
PL374378A1 (pl) Pochodne chinolinowe i ich zastosowanie jako ligandów 5-HT 6
HUP0300857A3 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
PL370657A1 (pl) Pochodne chinazolinonowe i ich zastosowanie jako agonistów CB
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
PL376363A1 (pl) Chiralne pochodne kwasu oksazoloarylopropionowegoi ich zastosowanie jako agonistów PPAR
AU2003283597A8 (en) Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
IL173521A0 (en) Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists
AU2003205558A1 (en) Thioibotenic acid and derivatives thereof
NO20031517D0 (no) Propionsyrederivater med PPAR-alfa aktiverende egenskaper
AU2003292381A1 (en) Naphthyridine derivatives and their use as fungicides
AU2003303678A1 (en) Urea derivatives and their use as anti-inflammatory agents
AU2003205963A8 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
IL169337A0 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
AU2002357084A1 (en) 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
HK1057041A (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20121006